The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.

Bardhan K, Anagnostou T, Boussiotis VA. · 2016

Read The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. by Bardhan K, Anagnostou T, Boussiotis VA. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5149523.txt.

Introduction

Kankana Bardhan, Theodora Anagnostou, and Vassiliki A. Boussiotis reviewed the PD-1 pathway in Frontiers in Immunology in 2016. PD-1 is a brake receptor on T cells, and its partners PD-L1 and PD-L2 sit on other cells; together they help keep the immune system from attacking the body's own tissues.

The same brake also shields viruses and tumors by damping T cell attack, which is why blocking it has become a major cancer therapy strategy. The review covers the pathway's parts, the signals PD-1 sends inside the T cell, and what those signals do to T cell growth and function. It frames the arc from the pathway's discovery in basic tolerance research to its present clinical use.

Catalog record

CREATORBardhan K, Anagnostou T, Boussiotis VA.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE92 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5149523

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation By Kankana Bardhan, Theodora Anagnostou, Vassiliki A. Boussiotis Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2016.00550 ABSTRACT The immune system maintains a critically organized network to defend against foreign particles, while evading self-reactivity simultaneously. T lymphocytes function as effectors and play an important regulatory role to orchestrate the immune signals. Although central tolerance mechanism results in the removal of the most of the autoreactive T cells during thymic selection, a fraction of self-reactive lymphocytes escapes to the periphery and pose a threat to cause autoimmunity. The immune system evolved various mechanisms to constrain such autoreactive T cells and maintain peripheral tolerance, including T cell anergy, deletion, and suppression by regulatory T cells (TRegs). These effects are regulated by a complex network of stimulatory and inhibitory receptors expressed on T cells and their ligands, which deliver cell-to-cell signals that dictate the outcome of T cell encountering with cognate antigens. Among the inhibitory immune mediators, the pathway consisting of the programed cell death 1 (PD-1) receptor (CD279) and its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273) plays an important role in the induction and maintenance of peripheral tolerance and for the maintenance of the stability and the integrity of T cells. However, the PD-1:PD-L1/L2 pathway also mediates potent inhibitory signals to hinder the proliferation and function of T effector cells and have inimical effects on antiviral and antitumor immunity. Therapeutic targeting of this pathway has resulted in successful enhancement of T cell immunity against viral pathogens and tumors. Here, we will provide a brief overview on the properties of the components of the PD-1 pathway, the signaling events regulated by PD-1 engagement, and their consequences on the function of T effector cells. INTRODUCTION The field of T-cell costimulation started with the “two-signal” theory of lymphocyte activation that was originally proffered to distinguish self from non-self. This model explains the process of activation or anergy when a naive T cell confronts an antigen (1, 2). As per this model, two signals from antigen-presenting cells (APCs) are required for effective activation of a naive T cell. The first signal confers specificity to the immune response and involves antigen recognition, provided by the interaction of antigenic peptide/major histocompatibility complex (MHC) with the T cell receptor (TCR). The second antigen-independent signal is the “costimulatory signal,” delivered by costimulatory molecules expressed on APCs to receptors expressed on T cells. If a T cell receives only antigen-specific TCR stimulation in the absence of costimulation, it will become unresponsive (anergic) to subsequent antigenic challenge (3, 4). Later, negative costimulatory (i.e., coinhibitory) signals were also found to exist. Receptors delivering coinhibitory signals function as immune checkpoints and play a decisive role in maintaining peripheral tolerance and impeding autoimmunity (5–8). The best-studied pathway for T cell costimulation includes B7-1/B7-2–CD28/CTLA-4 superfamily, which is essential for T cell activation and tolerance (9–13). While both the receptors and ligands of this superfamily are structurally type I transmembrane protein with a single IgV extracellular domain that predominantly mediates the receptor–ligand interaction, the ligands also contain an IgC domain on their outer surface. The immune system functions by maintaining an intricate balance between CD28/costimulation-mediated T cell activation and CTLA-4/immune checkpoint-mediated inhibition. Identification of the programed cell death 1 (PD-1) as another inhibitory receptor and inclusion of its ligands as additional members of the B7-1/B7-2–CD28/CTLA-4 family (14, 15) re-established the importance of immune checkpoints to safeguard the maintenance of T cell tolerance. Since the beginning of its discovery, costimulation had been of therapeutic interest because it was thought to provide a way to promote T cell activation to enhance antitumor responses. But with the discovery of CTLA-4 as a potent inhibitory immune checkpoint, the notion about cancer immunotherapy was modified and the preferred approach was understood as not to activate the immune system to attack cancer but to remove the coinhibitory signals that block antitumor T cell responses. Based on the same concept, the PD-1/PD-L1 coinhibitory pathway was exploited therapeutically resulting in remarkable outcomes with 20–90% response rates in multiple clinical trials and various types of cancer (16–19). DISCOVERY OF THE PD-1:PD-L1 PATHWAY While studies have shown that PD-1–PD-L interaction is important to maintain a balance between peripheral tolerance and autoimmunity, it also impairs viral and tumor immunity, promoting chronic infection and tumor progression. PD-1 is a 288 amino acid protein mostly expressed on the surface of activated T cells (20–23). In 1992, PD-1 was identified as an apoptosis-associated molecule (24). In an attempt to identify gene(s) important for apoptosis, Tasuku Honjo and colleagues at Kyoto University performed subtractive-hybridization assay and PD-1 cDNA was found to be encoded by all of the isolated clones. However, its overexpression had no effect on apoptosis in the studied cell lines (23). In 1999, the same group demonstrated PD-1 to be a negative regulator of immune responses by studying PD-1-deficient mice, which developed an autoimmune phenotype with delayed onset, organ-specific effects and incomplete penetrance. While CTLA-4 deficiency caused the rapid-onset of systemic autoimmunity, PD-1 deficiency resulted in spontaneous development of lupus like arthritis, splenomegaly, glomerulonephritis, increased number of B-lymphocytes and myeloid cells, and increased serum IgA, IgG2b and IgG3 in C57BL/6 mice. Interestingly, PD-1 deletion in Balb/c background resulted in a distinct autoimmune phenotype as early as of 5 weeks of age, with dilated cardiomyopathy, gastritis, and high circulating level of troponin reactive IgG1. PD-1 deficiency induced subacute type I diabetes in non-obese diabetic (NOD) mice whereas lethal myocarditis was observed in mice with MRL background (8, 25–27). Introduction of the lpr mutation, which causes absence of Fas-mediated apoptosis pathway (B6-lpr/lpr-PD-1−/−), expedited the commencement and severity of the disease. However, no disease was developed in Balb/c-PD-1−/− RAG−/− mice, showing the importance of lymphocytes for disease development. To study the response to autoantigens, PD-1-deficient 2C TCR transgenic mice were bred to the autoreactive background (H−2b/d) and the offspring displayed splenomegaly, growth retardation, and lethal graft versus host disease (GVHD) (7). The group collaborated with Genetics Institute at Cambridge, MA, USA, in an attempt to identify the ligand of PD-1. Almost in parallel, Lieping Chen’s group, then at Mayo Clinic, identified PD-L1, which was named B7-H1, as a molecule with homology to B7-1 and B7-2 (28). The group did not discover that B7-H1 is a ligand for PD-1 but reported that B7-H1 costimulates T cells via a receptor different from CD28, CTLA4, or ICOS and delivers an activation signal to T cells, which leads to IL-10 production, but not to detectable levels of IL-2. A third, independent research group led by Gordon Freeman at Dana–Farber Cancer Institute identified by database search a B7-like molecule that did not interact with CD28, CTLA4 or ICOS. The group collaborated with Genetics Institute at Cambridge, MA, USA, in order to identify its receptor. Through these interactions with the two independent groups, the researchers at Genetics Institute found that this B7-1 like molecule was a ligand for PD-1, and was then named PD-L1 (Pdcd1lg1, CD274) for PD-1 ligand 1 (14). The collaboration further identified the second PD-1 ligand, named PD-L2 (Pdcd1lg2, CD273) (15). MOLECULAR STRUCTURE Programed cell death 1 is composed of a single N-terminal IgV-like domain sharing 21–33% sequence identity with CTLA-4, CD28, and ICOS, about 20-amino acid stalk

Read the complete text